Loading clinical trials...

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus | Clinical Trials | Clareo Health

COMPLETED

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

NCT01950637•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•PATIENTS WITH T2DM:
•Diagnosed with type 2 diabetes by a healthcare professional
•Currently being treated with insulin medication, excluding premix insulin treatment
•Age at least 40 years
•Diagnosed as having type 2 diabetes over the age of 40
•HCPs:
•Primary care physician, diabetes specialist (diabetologist/endocrinologist) or diabetes specialist nurse/diabetes nurse educator
•Have a minimum of 2 years experience within current speciality
•See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists), of which at least 10 per month must be on modern (analogue) inulins

Locations (6)

Novo Nordisk Investigational Site

Princeton, New Jersey, United States

Novo Nordisk Investigational Site

Mississauga, Canada

Novo Nordisk Investigational Site

Copenhagen S, Denmark

Novo Nordisk Investigational Site

Mainz, Germany

Novo Nordisk Investigational Site

Tokyo, Japan

Novo Nordisk Investigational Site

Crawley, United Kingdom

Key Dates

Start Date

January 1, 2012

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

January 13, 2017

Enrollment

4,000

ACTUAL participants

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

No treatment given

BEHAVIORAL

survey

BEHAVIORAL

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions